vs
ICU MEDICAL INC（ICUI）与PLEXUS CORP（PLXS）财务数据对比。点击上方公司名可切换其他公司
PLEXUS CORP的季度营收约是ICU MEDICAL INC的2.2倍（$1.2B vs $540.7M），PLEXUS CORP净利率更高（4.3% vs -2.9%，领先7.2%），PLEXUS CORP同比增速更快（18.7% vs -14.1%），过去两年PLEXUS CORP的营收复合增速更高（7.2% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
Plexus Corp是总部位于美国密歇根州特洛伊市的软件企业，专注于开发及推广Plex制造云产品，这是一款面向制造行业的SaaS模式云计算ERP解决方案，可助力制造企业实现数字化运营管理升级。
ICUI vs PLXS — 直观对比
营收规模更大
PLXS
是对方的2.2倍
$540.7M
营收增速更快
PLXS
高出32.9%
-14.1%
净利率更高
PLXS
高出7.2%
-2.9%
两年增速更快
PLXS
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $1.2B |
| 净利润 | $-15.7M | $49.8M |
| 毛利率 | 37.5% | 10.2% |
| 营业利润率 | 1.0% | 5.3% |
| 净利率 | -2.9% | 4.3% |
| 营收同比 | -14.1% | 18.7% |
| 净利润同比 | 34.0% | 27.5% |
| 每股收益（稀释后） | $-0.63 | $1.82 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIPLXS
| Q1 26 | — | $1.1B | ||
| Q4 25 | $540.7M | — | ||
| Q3 25 | $537.0M | — | ||
| Q2 25 | $548.9M | — | ||
| Q1 25 | $604.7M | — | ||
| Q4 24 | $629.8M | — | ||
| Q3 24 | $589.1M | — | ||
| Q2 24 | $596.5M | — |
净利润ICUIPLXS
| Q1 26 | — | $41.2M | ||
| Q4 25 | $-15.7M | — | ||
| Q3 25 | $-3.4M | — | ||
| Q2 25 | $35.3M | — | ||
| Q1 25 | $-15.5M | — | ||
| Q4 24 | $-23.8M | — | ||
| Q3 24 | $-33.0M | — | ||
| Q2 24 | $-21.4M | — |
毛利率ICUIPLXS
| Q1 26 | — | 9.9% | ||
| Q4 25 | 37.5% | — | ||
| Q3 25 | 37.4% | — | ||
| Q2 25 | 37.9% | — | ||
| Q1 25 | 34.7% | — | ||
| Q4 24 | 36.1% | — | ||
| Q3 24 | 34.8% | — | ||
| Q2 24 | 34.8% | — |
营业利润率ICUIPLXS
| Q1 26 | — | 5.1% | ||
| Q4 25 | 1.0% | — | ||
| Q3 25 | 2.6% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 2.1% | — | ||
| Q4 24 | 6.0% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | 1.3% | — |
净利率ICUIPLXS
| Q1 26 | — | 3.8% | ||
| Q4 25 | -2.9% | — | ||
| Q3 25 | -0.6% | — | ||
| Q2 25 | 6.4% | — | ||
| Q1 25 | -2.6% | — | ||
| Q4 24 | -3.8% | — | ||
| Q3 24 | -5.6% | — | ||
| Q2 24 | -3.6% | — |
每股收益（稀释后）ICUIPLXS
| Q1 26 | — | $1.51 | ||
| Q4 25 | $-0.63 | — | ||
| Q3 25 | $-0.14 | — | ||
| Q2 25 | $1.43 | — | ||
| Q1 25 | $-0.63 | — | ||
| Q4 24 | $-0.97 | — | ||
| Q3 24 | $-1.35 | — | ||
| Q2 24 | $-0.88 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $303.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $1.5B |
| 总资产 | $4.1B | $3.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ICUIPLXS
| Q1 26 | — | $248.8M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $308.6M | — | ||
| Q3 24 | $312.5M | — | ||
| Q2 24 | $302.6M | — |
股东权益ICUIPLXS
| Q1 26 | — | $1.5B | ||
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $2.0B | — |
总资产ICUIPLXS
| Q1 26 | — | $3.2B | ||
| Q4 25 | $4.1B | — | ||
| Q3 25 | $4.1B | — | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.2B | — | ||
| Q4 24 | $4.2B | — | ||
| Q3 24 | $4.3B | — | ||
| Q2 24 | $4.3B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | — |
| 自由现金流经营现金流 - 资本支出 | $36.0M | — |
| 自由现金流率自由现金流/营收 | 6.6% | — |
| 资本支出强度资本支出/营收 | 4.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $91.8M | — |
8季度趋势，按日历期对齐
经营现金流ICUIPLXS
| Q1 26 | — | — | ||
| Q4 25 | $60.6M | — | ||
| Q3 25 | $56.7M | — | ||
| Q2 25 | $11.2M | — | ||
| Q1 25 | $51.3M | — | ||
| Q4 24 | $40.2M | — | ||
| Q3 24 | $36.1M | — | ||
| Q2 24 | $82.0M | — |
自由现金流ICUIPLXS
| Q1 26 | — | — | ||
| Q4 25 | $36.0M | — | ||
| Q3 25 | $27.6M | — | ||
| Q2 25 | $-8.5M | — | ||
| Q1 25 | $36.7M | — | ||
| Q4 24 | $16.1M | — | ||
| Q3 24 | $16.2M | — | ||
| Q2 24 | $62.5M | — |
自由现金流率ICUIPLXS
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | — | ||
| Q3 25 | 5.1% | — | ||
| Q2 25 | -1.5% | — | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 10.5% | — |
资本支出强度ICUIPLXS
| Q1 26 | — | — | ||
| Q4 25 | 4.6% | — | ||
| Q3 25 | 5.4% | — | ||
| Q2 25 | 3.6% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | 3.4% | — | ||
| Q2 24 | 3.3% | — |
现金转化率ICUIPLXS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.32× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
PLXS
| Asia-Pacific | $652.0M | 56% |
| Americas | $397.0M | 34% |
| Europe, Middle East and Africa | $116.0M | 10% |
